STUDY OF THE PROPERTIES OF THE MIXED WATER/SALT HOUSE DUST MITE ALLERGEN AIMING TO DESIGN ITS SUBLINGUAL FORM

Сurrent allergen-specific immunotherapy (AIT) is the most pathogenetically justified method of the IgE-dependent treatment of allergic diseases. Subcutaneous (SCIT) and sublingual (SLIT) AIT are currently used in wide clinical practice. Sublingual immunotherapy is characterized by the convenience of use, decreased incidence of systemic and local side effects, and proven clinical efficacy. However, sublingual form of home dust mite allergen for AIT is not yet produced in Russia. Previously, the technology for sublingual form of D. farinae (Der f) mites allergen was developed in our laboratory, and this extract was shown to be non-toxic and free of any significant side effects. We obtained a sublingual form of mixed D. pteronyssinus (Der р)/D. farina mites allergen for sublingually allergen-specific immunotherapy. We studied physico-chemical and immunobiological properties of the Der р and Der f mites phenol-free water-salt mixed extract (WWSME). WWSME was studied after sterilizing filtration. WWSME was analyzed by electrophoresis in polyacrylamide gel in the presence of dodecyl-sodium sulfate and reverse-phase high-performance liquid chromatography. ELISA was performed with polyclonal rabbit serum, obtained by sensitization of animals with recombinant Der f1 and Der f2 allergens. ELISA shows positive reaction of WWSME with IgG-antibodies of rabbits. We studied acute and chronic toxicity of received mixed allergen in laboratory animals. Pathomorphological studies have shown that WWSME has no detectable toxicity and does not cause local irritation in the animals. The WWSME product contains native proteins, retains immunogenic properties, is non-toxic and does not cause significant side effects. This extract can be used as the basis for designing a sublingual form of dust mite mixed allergen, which is especially promising for pediatric applications.

home dust mite allergens, Dermatophagoides pteronyssinus, Dermatophagoides farinae, sublingual form, allergy, allergenspecific immunotherapy

1. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А., Кобзев Д.Ю., Вачугова Л.К. Место аллергенспецифической иммунотерапии в лечении атопии // Consilium medicum, 2013. № 3. С. 55-61. [Аstafyeva N.G., Gamova I.V., Udovichenko E.N., Perfilova I.A., Kobzev D.Yu., Vachugova L.K. Place of the allergenspecific immunotherapy in the atopy’s treatment. Consilium medicum, 2013, no. 3, pp. 55-61. (In Russ.)]

2. Бержец В.М., Коренева Е.А., Петрова Н.С., Пищулина Л.А. Способ получения гранулированной лекарственной формы из аллергена клещей рода Dermatophagoides farinae // Патент на изобретение №: 2216353. 2002. С. 1. [Berzhets V.M., Koreneva E.A., Petrova N.S., Pishchulina L.A. A method of preparing a granular medicine form from Dermatophagoides farinae allergen. Рatent for innovation No. 2216353, 2002, р. 1.

3. Бжедугова Е.Р., Ненашева Н.М. Эффективность и безопасность сублингвальной аллерген-специфической иммунотерапии аллергенами клещей домашней пыли // Российский аллергологический журнал, 2008. № 6. С. 67-73. [Bzhedugova E.R., Nenasheva N.M. Efficacy and safety of house dust mite sublingual immunotherapy. Rossiyskiy allergologicheskiy zhurnal = Russian Allergology Journal, 2008, no. 6, pp. 67-73. (In Russ.)]

4. Воробьева О.В., Гущин И.С. Контролируемые исследования эффективности и безопасности аллерген-специфической иммунотерапии: исторический аспект // Российский аллергологический журнал, 2011. № 4. С. 3-14. [Vorobyeva O.V., Guschin I.S. Controlled trials of the efficacy and safety of allergen-specific immunotherapy: historical aspect. Rossiyskiy allergologicheskiy zhurnal = Russian Allergology Journal, 2011, no. 4, pp. 3-14. (In Russ.)]

5. Коровкина Е.С., Мокроносова М.А. Аллергия к клещам домашней пыли с позиций молекулярной аллергологии // Медицинская иммунология, 2012. Т. 14, № 4-5. С. 279-288. [Korovkina E.S., Mokronosova M.A. House dust mite allergy in view of molecular allergology. Meditsinskaya immunologiya = Medical Immunology (Russia), 2012, Vol. 14, no. 4-5, pp. 279-288. (In Russ.)] doi: 10.15789/1563-0625-2012-4-5-279-288.

6. Сублингвальная иммунотерапия. Меморандум Всемирной организации по аллергии (WAO) // Астма, 2010. Т. 11, № 1. С. 5-57. [Sublingual Immunotherapy: Memorandum WAO (WAO). Astma = Asthma, 2010, Vol. 11, no. 1, pp. 5-57. (In Russ.)]

7. Хутеева С.Х., Федосеева В.Н. Аллергенспецифическая иммунотерапия бронхиальной астмы. М.: Экон, 2000. С. 250. [Khuteeva S.Kh., Fedoseeva V.N. Allergen-specific immunotherapy of Asthma]. Moscow: Ekon, 2000, p. 250.

8. Park K.H., Son M., Choi S.Y., Park H.J., Lee J.H., Jeong K.Y., Lee J.S., Park J.W. In vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents. Allergy Asthma Immunol. Res., 2015, Vol. 7, no. 2, рр. 124-129.

9. Yuta A., Miyamoto Y., Ogihara H., Hattori R., Okubo K. Antigen specific sublingual immunotherapy for pediatric Japanese cedar pollinosis. Arerugi, 2009, Vol. 58, no. 2, рр. 124-132.